María del Val Bermejo Sanz-rekin lankidetzan egindako argitalpenak (28)

2024

  1. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

    Pharmaceutics, Vol. 16, Núm. 3

  2. Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole

    Pharmaceutics, Vol. 16, Núm. 5

2022

  1. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen

    International Journal of Pharmaceutics, Vol. 614

2021

  1. Nuevos hidrogeles para favorecer la cicatrización

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 175-176

2020

  1. Candesartan cilexetil in vitro–in vivo correlation: Predictive dissolution as a development tool

    Pharmaceutics, Vol. 12, Núm. 7, pp. 1-21

  2. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 18, pp. 1-30

2018

  1. Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System

    Biomacromolecules, Vol. 19, Núm. 4, pp. 1294-1304

2015

  1. Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers

    Journal of Pharmacological and Toxicological Methods, Vol. 71, pp. 21-32

2013

  1. Tratado general de biofarmacia y farmacocinética: Volumen I: LADME. Análisis farmacocinético. Biodisponibilidad y bioequivalencia

    Síntesis

2011

  1. Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model

    European Journal of Pharmaceutical Sciences, Vol. 42, Núm. 3, pp. 290-299

2009

  1. Unique pharmacology of KAR-2, a potential anti-cancer agent: Absorption modelling and selective mitotic spindle targeting

    European Journal of Pharmaceutical Sciences, Vol. 36, Núm. 1, pp. 11-19

2008

  1. Correlación entre modelos in vitro, in situ e in vivo en estudios de absorción

    Revista Médicas UIS, Vol. 21, Núm. 1

  2. Correlation Between In Vitro, In Situ, and In Vivo Models

    Biosimulation in Drug Development (Wiley-VCH Verlag GmbH & Co. KGaA), pp. 87-113

  3. Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy

    Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, Vol. 366, Núm. 1880, pp. 3599-3617

2006

  1. Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin

    International Journal of Pharmaceutics, Vol. 307, Núm. 1, pp. 33-41

2004

  1. PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones

    European Journal of Pharmaceutical Sciences, Vol. 21, Núm. 4, pp. 429-441

2003

  1. Estudio de la linealidad cinética del proceso de absorción de norfloxacino y ofloxacino en monocapas celulares de CACO-2

    VI Congreso de la Sociedad Española de Farmacia Industrial y Galénica. 3ª Jornadas de Tecnología Farmecéutica. Granada, 9-11 de febrero de 2003.: Libro de Comunicaciones (Comares), pp. 379-380

  2. Kinetic modeling of triamterene intestinal absorption and its inhibition by folic acid and methotrexate

    Journal of Drug Targeting, Vol. 11, Núm. 4, pp. 215-223

  3. Predicción de la permeabilidad intestinal: correlación in vitro-in situ para fármacos con mecanismos activos de secreción

    VI Congreso de la Sociedad Española de Farmacia Industrial y Galénica. 3ª Jornadas de Tecnología Farmecéutica. Granada, 9-11 de febrero de 2003.: Libro de Comunicaciones (Comares), pp. 441-442

  4. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: In vitro and in situ inhibition studies

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 55, Núm. 2, pp. 241-246